Injected human umbilical cord-derived mesenchymal stromal cells do not appear to elicit an inflammatory response in a murine model of osteoarthritis by Perry, J et al.
Osteoarthritis and Cartilage Open 2 (2020) 100044Contents lists available at ScienceDirect
Osteoarthritis and Cartilage Open
journal homepage: www.elsevier.com/journals/osteoarthritis-and-cartilage-open/2665-9131Injected human umbilical cord-derived mesenchymal stromal cells do not
appear to elicit an inflammatory response in a murine model
of osteoarthritis
J. Perry a,b, H.S. McCarthy a,b, G. Bou-Gharios c, R. van 't Hof c, P.I. Milner c, C. Mennan a,b,1,
S. Roberts a,b,*,1
a Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, SY10 7AG, UK
b School of Pharmacy and Bioengineering (PhaB), Keele University, Keele, ST4 7QB, UK






Xenogeneic* Corresponding author. Robert Jones & Agnes H
E-mail addresses: jade.perry3@nhs.net (J. Perr
liverpool.ac.uk (R. van 't Hof), P.I.Milner@liverpoo
1 Joint last author.
https://doi.org/10.1016/j.ocarto.2020.100044
Received 5 November 2019; Accepted 7 February 2
2665-9131/© 2020 Osteoarthritis Research Society
creativecommons.org/licenses/by/4.0/).S U M M A R Y
Objective: This study investigated the effect of hUC-MSCs on osteoarthritis (OA) progression in a xenogeneic
model.
Design: Male, 10 week-old C57BL/6 mice underwent sham surgery (n ¼ 15) or partial medial meniscectomy
(PMM; n ¼ 76). 5x105 hUC-MSCs (from 3 donors: D1, D2 and D3) were phenotyped via RT-qPCR and immu-
noprofiling their response to inflammatory stimuli.
They were injected into the mouse joints 3 and 6 weeks post-surgery, harvesting joints at 8 and 12 weeks post-
surgery, respectively. A no cell ‘control’ group was also used (n ¼ 29). All knee joints were assessed via micro-
computed tomography (μCT) and histology and 10 plasma markers were analysed at 12 weeks.
Results: PMM resulted in cartilage loss and osteophyte formation resembling human OA at both time-points. In-
jection of one donor's hUC-MSCs into the joint significantly reduced the loss of joint space at 12 weeks post-
operatively compared with the PMM control.
This ‘effective’ population of MSCs up-regulated the genes, IDO and TSG6, when stimulated with inflammatory
cytokines, more than those from the other two donors.
No evidence of an inflammatory response to the injected cells in any animals, either histologically or with plasma
biomarkers, arose.
Conclusion: Beneficial change in a PMM joint was seen with only one hUC-MSC population, perhaps indicating
that cell therapy is not appropriate for severely osteoarthritic joints. However, none of the implanted cells
appeared to elicit an inflammatory response at the time-points studied. The variability of UC donors suggests
some populations may be more therapeutic than others and donor characterisation is essential in developing
allogeneic cell therapies.1. Introduction
Osteoarthritis (OA) is not only the most common musculoskeletal
disorder in our society but is also seriously debilitating, impacting more
on an individual's quality of life than cancer, diabetes or heart disease
[1]. Despite this, the most frequent treatment option for patients is
arthroplasty at the end stage of the disease, replacing the degenerate joint
with an inert prosthetic device, which has a finite lifespan. With anunt Orthopaedic Hospital NHS Fo
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International (OARSI). Publishedincreasingly aged society, more arthroplasties are requiring revision and
replacement year on year; these are more challenging, more expensive
and less successful than the original surgery [2]. A biological approach
could provide an earlier and more permanent solution.
Autologous chondrocyte implantation (ACI) has been used for over
two decades for treating more discrete chondral or osteochondral defects
in the knee [3,4], which if left untreated often progress to end stage
osteoarthritis [5]. Although ACI has recently been reported to beundation Trust & PhaB (Keele University), Oswestry, Shropshire SY10 7AG, UK.
.S. McCarthy), G.Bou-Gharios@liverpool.ac.uk (G. Bou-Gharios), R.Vanthof@
n@nhs.net (C. Mennan), sally.roberts4@nhs.net (S. Roberts).
by Elsevier Ltd. This is an open access article under the CC BY license (http://
J. Perry et al. Osteoarthritis and Cartilage Open 2 (2020) 100044cost-effective [6], an autologous cell therapy product is much more
restrictive in terms of production costs, logistics and donor site morbidity
than an allogeneic cell therapy product. Hence, development of an
allogeneic treatment could have many advantages, with cells from tissues
earlier in development for example having potential advantages over
those obtained from more mature individuals [7]. We have previously
characterised mesenchymal stromal cells (MSCs) isolated from whole
human umbilical cord (UC) and shown them to have a greater prolifer-
ative capacity and equivalent immunomodulatory ability (in terms of
gene expression of indoleamine 2,3-dioxygenase (IDO) and human
leukocyte antigen (HLA)-G than MSCs derived from adult human bone
marrow [8,9].
Studying the aetiopathogenesis of OA in humans remains a challenge,
as there is restricted availability of diseased tissues particularly at the
early stage of OA. As a result of this, animal models remain an increas-
ingly popular choice for basic science studies to identify the underlying
molecular mechanisms of OA, along with studying pharmacological in-
terventions longitudinally. While spontaneous OA models exist (e.g. in
mice, guinea pigs and dogs) [10–12], surgical models can provide
numerous advantages, including reduced variability, reduced reliance on
genotype and a faster onset of disease. This generally results in shorter
study durations and therefore lower husbandry costs. The partial medial
meniscectomy (PMM) and medial collateral ligament transection (MCLT)
models were the first surgical instability models described in the mouse
[13]. In C57BL/6 mice, the PMMmodel has been shown to produce mild
degenerative changes by 2–4 weeks post-surgery, progressing to more
severe degenerative changes by 8 weeks [14,15], mimicking the patho-
genesis of traumatic OA in humans, rapidly resulting in end-stage OA.
In the present study, we evaluate the effect of an intra-articular in-
jection of human UC-MSCs on the severity of disease and inflammatory
response in the PMM murine model of end-stage OA. Individual MSC
populations were obtained from three humans and characterised via
their immunoprofile and response to inflammatory mediators to study
differences between donors.
2. Materials and methods
2.1. Human umbilical cord MSC culture
Umbilical cords (n ¼ 3; donors D1, D2 and D3) were obtained within
24 h of natural delivery following informed patient consent (ethical
approval: 10/H10130/62), as previously described [8]. The human cord
donors were aged 24, 31 and 33 years at the time of harvest and all had a
healthy BMI (19.7–23.2). Cells were obtained from 2 to 3 cm of UC
digested with type 1 collagenase (1 mg/mL, > 125 digesting units/mg
wet weight; Sigma, UK) for 1 h at 37C, before seeding into tissue culture
flasks at 5103/cm2 and culturing in Dulbecco's Modified Eagle's Me-
dium (DMEM/F12, Gibco, UK) containing 1% (v/v) penicillin and
streptomycin (P/S, Life Sciences, UK) and 10% (v/v) foetal calf serum
(FCS; Life Sciences, UK). Cells cultured were maintained in a humidified
environment at 5% CO2, changing media every 2–3 days and culturing
cells to passage (P) 3.
2.2. Immunoprofiling of UC-MSCs
The immunoprofile of the UC cell populations at P3 (n ¼ 3) was
assessed using flow cytometry, as previously described [8]. Unless other-
wise stated all antibodies were purchased from Becton Dickinson &
company (BD), Oxford, UK. In brief, cells were stained with the following
antibodies against CD14, CD19, CD34, CD45, HLA-DR, CD73, CD90,
CD105 [16,17]. Cells were also assessed for other markers indicative of
MSC-related behaviour (CD271, Receptor Tyrosine Kinase-like Orphan
Receptor 2 (ROR2) and Fibroblastic Growth Factor Receptor 3 (FGFR3), all
R&D systems, Abingdon, UK), putative chondrogenic markers (CD151,
CD39, CD44, CD49c, CD163, CD166) and immunomodulatory markers,
CD106 and CD317 (eBioscience UK) [18–20]. Co-stimulatory markers2
CD40, CD80, CD86 were also assessed, before and after stimulation with
inflammatory cytokines, as well as HLA-DR, CD39, CD73, CD106 and
CD317 as these markers are known to change upon inflammatory stimulus
[21]. Appropriate isotype-matched IgG controls were used throughout,
analysing approximately 100,000 cells for each antibody using a FACS-
Canto II flow cytometer and FACS DIVA 7 software (BD).
2.3. Reverse transcriptase-quantitative polymerase chain reaction (RT-
PCR) of UC-MSCs’ inflammatory response
hUC-MSCs were exposed to either 25 ng/mL interferon gamma (IFN-
γ) or an “inflammatory cocktail” (containing 25 ng/mL IFN-γ, 10 ng/mL
interleukin (IL)-1β and 50 ng/mL tumour necrosis factor (TNF)-α) for
24 h prior to harvesting.
RNA was extracted, converted to cDNA and the expression of IDO and
TNF-stimulating gene (TSG)-6 was assessed as previously described [9].
The relative fold change in expression for IDO and TSG6 following
stimulation was determined using the comparative CT method [22].
2.4. Animals
Male, 30 g, ten-week-old C57BL/6 wild type mice ((n ¼ 91) Harlan
Laboratories, UK), were randomly assigned to either control or experi-
mental groups, and group housed (4 mice per cage) at the University of
Liverpool in a climate controlled room in ventilated polypropylene cages,
with 12 h light/dark cycles and provided with ad libitum water and food.
Animals were culled at 18–22 weeks of age. All experimental procedures
complied with the 1986 Animals (Scientific Procedures) Act and the
ARRIVE guidelines [23]. The University of Liverpool Animal Welfare
Committee approved the animal usage and protocols used throughout the
study under Home office Licence PPL70/9047.
2.5. Induction of OA
The modified PMM model was performed similar to that previously
described, and the timings organised so that the joints were harvested at
the usual endpoints of 8 and 12 weeks [14,24]. Mice were anaesthetised
via inhalation of isoflurane and oxygen under aseptic conditions. A small
(3–5 mm) medial para-patellar skin incision was made in the left hind
limb with a number 11 scalpel blade. The anterior horn of the medial
meniscus was released from the tibial plateau through transection of the
medial meniscotibial ligament (MMTL). This displacement was
confirmed with forceps and the incision closed (muscle/fascia to medial
edge of the patellar ligament) with synthetic absorbable sutures (8-0
polyglactin 910 (Surgicryl)) before suturing intra-dermally (again with
8-0 polyglactin 910) to close the skin. Sham operated mice were treated
the same, but the meniscus was left intact after identification. Following
the procedure all mice were administered pain relief (buprenorphine
0.1 mg/kg intramuscular injection) and antimicrobials (enrofloxacin
5 mg/kg subcutaneous injection).
2.6. Cell application
Mice were monitored for 3 weeks post-surgery for behavioural
changes or poor wound healing. At 3 or 6 weeks, hUC-MSCs (5x105 cells
in 10 μl DMEM/F12) derived from three patient donors (D1, D2 and D3,
as previously described) were injected intra-articularly to the PMM
treatment groups; no cells were administered in the sham or PMM control
groups (Fig. 1 & Table 1). All injections were performed under anaes-
thesia via inhalation of isoflurane and oxygen.
2.7. Sample preparation
Following anaesthesia via inhalation of isoflurane and oxygen, mice
were sacrificed by cervical dislocation and blood was collected (at the 12
week time-point only) via cardiac puncture and the plasma stored at
Fig. 1. Experimental design: hUC-MSCs were injected into the hind left knee of C57BL/6 mice at either 3 or 6 weeks post-PMM (time points 1 and 2, respectively);
mice were culled at 8 and 12 weeks post-PMM for time points 1 and 2 respectively. Sham operated mice and PMM control mice were also included, with neither of
these receiving hUC-MSCs.
Table 1
Treatment groups at 8 and 12 weeks.
Group 8 weeks 12 weeks
PMM SHAM PMM SHAM
D1 hUC-MSCs 8 – 6 –
D2 hUC-MSCs 6 – 7 –
D3 hUC-MSCs 8 – 12 –
No Cell Controls 11 11a 18a 4
Totals 33 11 43 4
n ¼ 44 n ¼ 47
D ¼ donor.
a one mouse died in each of these groups.
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v/v) overnight, stored in 70% ethanol and scanned using a Skyscan 1272,
μCT scanner (Bruker, Belgium), as previously described [25]. Scans were
reconstructed using NRecon (Skyscan, Bruker, Belgium) and 3D volumes
of interest (VOI) were identified using Dataviewer (Skyscan) and ana-
lysed using CTAn software (Skyscan). Morphometric parameters were
analysed for the tibial subchondral bone epiphysis (medial/lateral Bone
Volume (BV, μm [3]), Bone Volume/Tissue Volume (BV/TV as a %),
subchondral bone thickness (Tb.Th, μm), total joint space (μm), osteo-
phytes (both number and volume (μm3)) and total bone volume (μm3)),
as previously described [25,26]. After μCT scanning, the knee joint
specimens were returned to formalin overnight, decalcified in 200 mM
EDTA for 2 weeks before transferring to 70% ethanol. Fully extended
knee joints were then embedded in paraffin wax and coronally sectioned
(5 μm).
2.8. Assessment of cartilage degeneration and synovitis
All histology was anonymised and scored by three blinded observers.
Every tenth knee joint section was stained with safranin-O and fast green
and scored using the Osteoarthritis Research Society International
(OARSI) score [27]. In each section, four quadrants of the joint (medial
femoral condyle (MFC), lateral femoral condyle (LFC), medial tibial
plateau (MTP) and lateral tibial plateau (LTP)) were scored on a
semi-quantitative scale from 0 to 6 (0 representing a healthy joint and 6 a
severely degenerate joint). A minimum of 8 sections were scored per
mouse and the highest three scoring sections throughout the knee joint
were summed and averaged between scorers, to yield a maximum joint
score of 72 [27].
Synovitis was evaluated on a single haematoxylin and eosin (H&E)-
stained central section of the joint and assessed across all four quadrants
using a modified version of a previously established scoring system [28].
A score for sub synovial stroma was included [29] whilst bone erosion
was excluded (Supplementary Table 1). An immunohistochemical study
was also performed on paraffin embedded sections, staining with
anti-human emerin (antibodies kindly provided by Dr Heidi Fuller,
Oswestry/Keele, see Supplementary data), to determine the presence of
hUC-derived MSCs. (A positive control was produced by injecting 100,3
000 hUC-MSCs in 10 μL of medium into a mouse joint which was
immediately sacrificed).2.9. Biomarker analysis
Conditioned media from hUC-MSC cell cultures, of both stimulated
(with an inflammatory cocktail and IFN- γ) and unstimulated cells, were
analysed in triplicate for human GM-CSF, IL-1RA, IL-4, IL-6, IL-8, IL-10,
IP-10, MCP-1, VEGF, SDF-1α using a custom-designed panel from
MesoScale Discovery (MSD; Gaithersburg, MD, USA; see Supplementary
Table 2). Mouse plasma samples from the 12 week time-point were
assayed in duplicate for murine GM-CSF, IL-1β, IL-4, IL-6, IL-10, TNF-α,
IFN-γ, MCP-1, VEGF and TGF-β3. All MSD plates were carried out ac-
cording to the manufacturer's instructions and were read using the MSD
Sector Imager 2400 and analysed with MSD Discovery Workbench soft-
ware version 3.2.10. Statistical analysis
All data were analysed using GraphPad Prism 8 (San Diego, USA) and
tested for normality prior to analysis. Results are expressed as the
mean  standard deviation. Parametric data was analysed by one-way
repeated-measures analysis of variance (ANOVA) with multiple com-
parisons using Tukey's correction. Non-parametric data was analysed
using a Kruskal-Wallis test with Dunn's post-analysis correction with
multiple comparisons. Significance was determined as p < 0.05.
3. Results
3.1. Immunoprofiling and immunomodulatory gene expression of hUC-
MSCs
All 3 donors had similar profiles for markers indicative of MSCs,
immunomodulation and chondrogenesis. However, the hUC-MSCs did
not strictly adhere to the ISCT criteria for MSCs, as CD14 was slightly
elevated (mean 4.4 0.97% production; Fig. 2A). Importantly, following
stimulation with an inflammatory cocktail, there was no detectable
production of HLA-DR or the co-stimulatory markers (CD40, CD80 and
CD86), the presence of which may elicit an immune response in vivo.
Production of the immunomodulatory markers CD39, CD106 and CD317
were increased on hUC-MSCs following inflammatory stimulus, whereas
immunopositivity for CD14 and CD73 remained unchanged (Fig. 2B).
IDO expression (Fig. 2C and E) was upregulated in all hUC-MSCs donors,
to varying degrees, following stimulation with IFNγ or the inflammatory
cocktail. Similar results were found for TSG6 expression (Fig. 2D) with
the inflammatory cocktail, apparently independent of age or BMI of the
donor. hUC-MSCs from D1 elicited the greatest response to IFNγ and the
inflammatory cocktail compared to the other 2 donors, with regards to
IDO and TSG6 expression (Fig. 2C–E).
Fig. 2. Characterisation of hUC-MSCs prior to use in the PMM model. Immunoprofiling of hUC-MSCs assessed via flow cytometry for markers indicative of MSCs,
putative chondrogenic markers and immunomodulation on un-stimulated cells (A). Markers indicative of MSCs (CD14, CD73), co-stimulation (CD40, CD80, CD86),
Human Leukocyte Antigen-DR (HLA-DR) and immunomodulation (CD106, CD317) on hUC-MSCs cultured in normal media without IFN-γ (unstimulated), following
stimulation with 25 ng/ml IFN-γ for 24 h and following stimulation with 25 ng/ml IFN-γ, 50 ng/ml TNF-α 10 ng/ml IL-1β for 24 h (inflammatory cocktail; B). RT-qPCR
analysis showing gene expression in stimulated and un-stimulated hUC-MSCs for TSG6 (stimulated with inflammatory cocktail for 24 h; C), IDO (stimulated with IFN-
γ for 24 h; D) and IDO (stimulated with inflammatory cocktail for 24 h; E). Data is presented as the mean  SD. Results are shown from 3 patients' hUC-MSCs, (D1-3).
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Fig. 3. Assessment of joint space.
Representative two-dimensional coronal
μ-CT images at 12 weeks in sham (A)
and PMM control group (B). The medial
joint space of the different groups ana-
lysed by μ-CT at 8 weeks (C) indicated
that all PMM groups, other than those
injected with hUC-MSCs from donor D2
had a significantly reduced joint space
(μm) compared to the sham control; in
contrast, at 12 weeks (D) the mice
injected with hUC-MSCs from donor D1
had a significantly greater joint space
than the PMM control, but it was not
significantly reduced compared to the
sham control. Data is presented as the
mean  SD. Significance was deter-
mined below p < 0.05.
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changes on μCT post-PMM surgery
Virtual sections in the coronal plane of the three-dimensional re-
constructions of the joints obtained from μCT analyses are shown in
Fig. 3A and B. Micro-CT analysis revealed osteoarthritic changes in all
PMM joints, with joint space narrowing and osteophyte formation
evident at 8 weeks post-PMM and loss of joint space becoming progres-
sively worse at 12 weeks after surgery. The injection of hUC-MSCs from
the 3 cord donors resulted in variable outcomes in the treated mice. The
mean joint space following PMM on the medial side in the PMM control
group was significantly less than sham operated knees at both 8 weeks
(PMM ¼ 5.1  6.7 μm, sham ¼ 41.5  8.0 μm; p ¼ 0.0015; Fig. 3C) and
12 weeks (PMM ¼ 2.3  3.8 μm; sham ¼ 50.9  7.2 μm; p ¼ 0.0008;
Fig. 3D). At 8 weeks, cell-treated PMM groups had a similar joint space to
the PMM controls but at 12 weeks there was a significantly larger joint
space in mice treated with cells from D1 compared to PMM control
(p ¼ 0.0374), but not with cells from D2 or D3. The D1 joint space was
also not significantly different to the sham group. On the lateral side of
the joints at both the 8 and 12 week time-points, no significant differ-
ences were observed between any of the groups.
There were significantly more osteophytes in all PMM joints (Fig. 4)
than sham operated knees at 8 weeks, whilst at 12 weeks, only joints that
received hUC-MSCs from donor D3 and the PMM control had significantly
more osteophytes than the sham control (p ¼ 0.0443 and p ¼ 0.0407,
respectively, Fig. 4B). Mice receiving hUC-MSCs from donors D1 and D2
had fewer osteophytes than the PMM controls, but this was not significant.5
Furthermore, onlymice that received hUC-MSCs from donor D2 at 8 weeks
(p¼ 0.0210; Fig. 4C) had an increased total osteophyte volume compared
with the sham, this difference was not seen with other PMM operated
groups at either time point (Fig. 4C and D).
At 8 weeks, administration of cells from D1 demonstrated a signifi-
cantly higher medial/lateral BV than sham mice (p ¼ 0.0109, Fig. 5A),
whilst cells from D3 demonstrated a significantly higher lateral trabec-
ular thickness than PMM control (p ¼ 0.0417, Fig. 5C), with no further
significant differences observed for any other treatment group or time
point (Fig. 5B and D). Additionally, there were no observed changes in
BV/TV throughout the experiment; however, as is normal for C57BL/6
mice (van t’ Hof, unpublished data), the medial side of the joint consis-
tently yielded a slightly higher percentage of bone (BV/TV %) than the
lateral side (data not shown).
3.3. Histological analyses of joint changes after PMM surgery
At 8 weeks but not 12 weeks post-PMM, all groups (hUC-MSCs) had
a significantly higher (worse) summed joint score than the sham control
(Figs. 6A–B, G-I). The maximumOARSI scores for the MFC andMTPwere
also significantly higher for all the PMM groups compared to the sham at
8 weeks but not at 12 weeks (Figs. 6C–F). At neither time-point were
there any significant differences on the lateral side between the different
groups (data not shown). There were no significant differences in syno-
vitis scores between any of the experimental groups or controls at either 8
or 12 weeks post-PMM (Fig. 7), with no indication of any inflammatory
response. There was no evidence of any staining for human emerin in any
Fig. 4. Quantification of osteophyte development. There were significantly more osteophytes in all cell groups at 8 weeks (A) but only D3 at 12 weeks (B). Total
osteophyte volume was only significantly increased in animals that received hUC-MSCs from donor D2 at 8 weeks (C); there were no significant differences in any
group at 12 weeks (D). Data is presented as the mean  SD. Significance was determined below p < 0.05.
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the positive controls (see Supplementary data).3.4. Inflammatory markers
All the inflammatory markers in the hUC-MSC conditioned media
samples were found to be within the detectable range, but only MCP-1
and IP-10 levels were significantly increased following stimulation
with an inflammatory cocktail compared to the unstimulated hUC-MSCs
(Fig. 8). In contrast, the levels of inflammatory markers in all murine
plasma samples from the 12 week time-point were typically found to be
below the lower limit of detection (LLOD) with the exception of MCP-1,
VEGF and TNFα but this was not significantly different between groups of
mice.
4. Discussion
The PMM model as a joint instability model is more severe than the
well-established destabilised medial meniscus (DMM) model of OA [24],
leading to a faster and more acute onset of OA within 2 weeks compared
to 4 weeks in the DMMmodel [14,15]. Welch et al. (2009) demonstrated
that the PMM yielded a greater (worse) OA histological score compared
with the DMM model over a 10 week period [15,30]. In our study the
total joint OARSI scores were significantly higher in all PMM joints
compared with sham joints at both 8 and 12 weeks. This, as well as
moderate to severe cartilage damage being observed on the medial side6
of the joint but less so on the lateral side, is in agreement with previous
studies [15,31].
Evidence of synovitis can be observed in 89% of patients with knee
OA detected by MRI [32]. Synovitis is increasingly recognised in the
pathogenesis of OA, being linked to disease severity in the knee [33]. At
both 8 and 12 weeks post-PMM surgery a low level of synovitis persisted
but this was not significantly different to mice that received sham sur-
gery. Similar results have been shown in the DMM instability model, with
Huesa et al. (2016) observing no differences in synovitis between the
DMM and sham group 4 weeks post-surgery [25]. Furthermore, Jackson
et al. (2014) suggested that the level of synovitis continually decreases in
DMM and sham control groups up to 16 weeks post-surgery [28].
Therefore despite utilising a more severe OA model, these results concur
with those of others. In addition, the lack of evidence for invasion by
inflammatory cells in the synovium or other joint tissues and lack of
increased levels of inflammatory markers in any of the plasma samples,
suggests that the hUC-MSCs did not evoke an inflammatory response in
any of the animals, at least at the time-points measured.
All three populations of hUC-MSCs utilised in this study adhered to
the ISCT criteria for MSCs, in terms of all their properties (differentiation
potential, plastic adherence and immunoprofile), apart from for the CD14
epitope, which was slightly elevated. We have found previously that
CD14 is often elevated onMSCs from bonemarrow, synovium and fat pad
[34,35]. Following stimulation of hUC-MSCs with IFN-γ and the in-
flammatory cocktail, our analysis of immunomodulatory gene expression
was found to be variable between the 3 donor populations tested. IDO is
Fig. 5. Subchondral bone changes.
hUC-MSCs from D1 demonstrated a
significantly higher medial/lateral BV
than sham mice at 8 weeks (A) but not
at 12 weeks (B). When looking at sub-
chondral bone thickness, cells from D3
demonstrated a significantly higher
lateral trabecular thickness than the
PMM control at 8 weeks (A) but not 12
weeks (D) with no further significant
differences observed for any other
treatment group or time point. There
were no significant differences in any
group at 8 or 12 weeks when looking at
subchondral bone thickness on the
medial side. Data is presented as the
mean  SD. Significance was deter-
mined below p < 0.05.
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tryptophan in the kynurenine pathway, suppressing T-cells and damp-
ening down an inflammatory response [36]. Our study, as shown previ-
ously, demonstrates that under normal culture conditions without
inflammatory stimulus, MSCs do not express IDO. However, following an
inflammatory stimulus such as exposure to IFN-γ, their IDO production is
activated [9,37,38]. TSG6, which is induced by TNFα, was also upregu-
lated by the hUC-MSCs following stimulation with an inflammatory
cocktail. TSG6 is a hyaluronan binding protein and is well known for its
potent chondroprotective and anti-inflammatory effects in arthritis [39,
40]. The ISCT working proposal also advises that characterisation of stem
cells should include activation or ‘licensing’, which involves stimulation
with IFN-γ, either alone or with the addition of TNF-α [21]. As we and
others have shown previously, the amount of up-regulation of IDO in
response to an inflammatory stimulus varies between donors, and in this
study the cells from donor D1 demonstrated the strongest response to the
inflammatory stimuli with the highest up-regulation of IDO and TSG6 [9,
38]. This could perhaps be an explanation of the apparent joint protec-
tion at 12 weeks post-PMM with regards to joint space narrowing and
osteophyte formation in joints treated with this particular population of
cells. François et al. (2012) have also suggested that the variation in
effectiveness of MSCs reported in clinical trials is likely to be due to
intrinsic variability in the immunosuppressive potential of each MSC
donor [38]. As far as we are aware, no other in vivo studies have char-
acterised this inflammatory response of cells for use in cartilage repair.
This novel aspect of this study used UC-MSC donors with vastly different
responses to inflammatory cytokines with respect to up-regulation of IDO
and TSG6.
Additionally, it is important to note that the co-stimulatory markers
(CD40, 80 and 86) as well as HLA-DR, were not expressed by any of the7
cell populations prior to, or after stimulation with either IFN-γ alone or
the inflammatory cocktail in the present study. The expression of these
markers are particularly undesirable on cells destined for allogeneic
therapies, as they are all expressed on antigen presenting cells of the
immune system, with CD40 also being found on tumour cells [41].
Monocyte chemoattractant protein-1 (MCP-1; also known as CCL2), is
a chemokine that was first described for its ability to induce monocyte
recruitment, via transendothelial migration, to sites of inflammation by
interacting with its receptor, CCR2, found on monocytes. Subsequently
MCP-1, has been shown to induce fibroblast proliferation, recruit mem-
ory T-lymphocytes and natural killer (NK) cells as well as promote the
cellular migration of MSCs [42,43]. Previous work demonstrates that
MCP-1 levels in synovial fluid (SF) samples has a moderately positive
correlation with radiographic knee OA changes [44] and OA symptom-
atic severity (as assessed by the Western Ontario and McMaster Univer-
sity Osteoarthritis Index (WOMAC) score) [45]. Furthermore, in the
MRL-lpr mouse model of arthritis, treatment with an MCP-1 antagonist,
MCP-1 (9–76), prior to disease onset greatly reduced OA progression
whereas native MCP-1 enhanced the onset and aggravated joint inflam-
mation [46]. In our study, following stimulation with an inflammatory
cocktail the levels of MCP-1 were significantly increased in hUC-MSCs
(particularly those from donors 2 and 3 (D2 and D3)) compared with
the un-stimulated hUC-MSCs. This could potentially explain the slight
joint protection seen in mice receiving cells from donor D1, with regards
to joint space narrowing, with these cells not significantly increasing
MCP-1 expression.
Interferon-y-inducible protein 10 (IP-10, also called CXCL10) is an
inflammatory chemokine inducible by IFN-γ and TNFα. Following stim-
ulation with IFN-γ we saw a large increase in IP-10 levels and even more
so with the combination of IL-1β, IFN-γ and TNFα, particularly for cells
Fig. 6. Assessment of cartilage degradation. The summed joint score was significantly higher than the sham for each cell group at 8 weeks (A) but not 12 weeks (B).
The maximum scores for the MFC and MTP were also significantly higher than sham and PMM control for each cell group at 8 weeks but not 12 weeks (C–F).
Histological changes with extreme loss of GAG (as seen by loss of safranin O staining) and loss of articular cartilage in the mouse knee can be seen in the medial
femoral condyle (MFC) and medial tibial plateau (MTP) in the control PMM knee with ‘no cells’ (G) and to a lesser extent in the PMM knee with donor D1 cells (H). No
loss of GAG was seen in the sham knee (I). Data is presented as the mean  SD. Significance was determined below p < 0.05. All sections were stained with safranin O
and fast-green counterstain.
J. Perry et al. Osteoarthritis and Cartilage Open 2 (2020) 100044from donors 2 and 3 (D2 and D3). Previous work demonstrated that IP-10
is increased in numerous arthritic diseases, including rheumatoid
arthritis, and can hone leukocytes to inflamed tissues [47]. IP-10 can also
promote osteoclastogenesis, by inducing RANKL in activated CD4þ
T-cells [48] leading to the erosion of bone and exacerbation of inflam-
mation. When selecting and banking MSCs for allogeneic therapies, it is
important to determine their response to inflammatory stimuli, as lower
production of MCP-1 and IP-10 may be more desirable for the treatment8
of arthritic patients and other inflammatory diseases [47,48].
Donor-donor variation is not uncommon and the varying degrees of
immunosuppressive potential could be due to an intrinsic disparity in
sensitivity and plasticity of the cells to inflammatory cytokines [38]. This
stresses the importance of cell characterisation when creating cell banks
for allogeneic therapies. Should cells be transplanted into an inflamma-
tory environment, or if the primary mechanism of therapeutic action is
immunomodulation, then understanding the immunomodulatory
Fig. 7. Assessment of synovial reaction: No significant synovitis was detected at either 8 (A) or 12 (B) weeks post-PMM surgery. Data is presented as the mean  SD.
Fig. 8. Inflammatory markers. Conditioned
media was collected from the following
hUC-MSC cell cultures: un-stimulated, stim-
ulated with IFN-γ (25 ng/ml for 24 h) and
stimulated with an inflammatory cocktail
(25 ng/ml IFN-γ, 50 ng/ml TNF-α 10 ng/ml
IL-1β for 24 h) and assessed for the presence
of: Monocyte chemoattractant protein 1
(MCP-1; A) and IFN-γ-inducible protein 10
(IP-10; B). MCP-1 and IP-10 were signifi-
cantly increased following stimulation with
an inflammatory cocktail for 24 h, compared
with the unstimulated UC-MSCs. Data is
presented as the mean  SD. Significance
was determined below p < 0.05. ▪ ¼ donor
D1; ▴ ¼ donor D2; ● ¼ donor D3.
J. Perry et al. Osteoarthritis and Cartilage Open 2 (2020) 100044potential is vital.
Pre-clinical OA models are helpful for predicting treatment response
and other outcome measures. However, no disease model has the ca-
pacity to completely and accurately mimic the human condition with
regards to pathogenic mechanisms, treatment methods and responses.
For example, when a human patient presents in the clinic with degen-
eration resulting in/from malalignment or a destabilised knee joint, an
orthopaedic surgeon is likely to stabilise the joint (e.g. through an
osteotomy, or meniscal repair/transplantation) prior to or whilst simul-
taneously performing cell therapy. In contrast, in our study, hUC-MSCs
were injected into unstable joints with a greater degree of disease
severity, more akin to end-stage OA in the human. Perhaps the lack of
improvement in joint health with all cell populations used indicates that
cell therapy is inappropriate for end stage OA, at least for reversing major
structural changes.
While it is evident from our study that the injected hUC-MSCs may
not be able to ameloriate osteophyte formation, or prevent complete
cartilage damage following a PMM, they do not appear to advance the9
pathogenesis of the disease. This supports the hypothesis that a me-
chanical instability model such as the PMM may be too severe to over-
come [49]. Therefore, it may be appropriate to determine whether
hUC-MSCs can improve osteochondral defects that lead to secondary
OA, or use a milder OA pre-clinical model to determine their effective-
ness as a cell therapy.5. Study limitations
Limitations of the model include the late stage time course,
speed of disease onset and the fact that blood was only collected at
the 12 week time-point. In addition and as in many other studies,
only male mice were used in this study as they typically develop
more severe cartilage degradation when compared with females, in
both spontaneous and surgically induced OA models [50]. A
further possible limitation is that pain was not assessed in this
study.
J. Perry et al. Osteoarthritis and Cartilage Open 2 (2020) 1000446. Conclusion
In conclusion, our results demonstrate that although the transplanted
hUC-MSCs did not all recover joint damage induced by the PMM as
assessed histologically, the implanted cells did not appear to elicit an
inflammatory response in the treated mice at the time-points studied
here. Furthermore, there was marked variability between the UC donors,
with significant reduced loss of joint space at 12 weeks being seen with
one donor's cells. This suggests that some donors' cells may have a greater
therapeutic potential than others, highlighting the importance of donor
cell characterisation for allogeneic cell therapies. Of course, the use of a
less severe OAmodel might bemore appropriate than themodel of severe
OA as used here, thus enabling a greater insight into the effectiveness of
hUC-MSCs in the prevention or delay of the development of this disease,
at least in the murine knee joint.
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